• Increase font size
  • Default font size
  • Decrease font size

Inhibitex to Host Conference Call to Report Second Quarter 2009 Financial Results on August 11, 2009

Print E-mail
Monday, 27 July 2009 16:08

ATLANTA--Inhibitex, Inc. (NASDAQ: INHX) announced today that it will host a conference call on Tuesday, August 11, 2009 at 9:00 a.m. EDT to review the Company’s second quarter ended June 30, 2009 financial results and provide an update on recent corporate developments. The Company will issue a press release regarding its financial results on the same day, prior to the conference call.

Webcast Information

To access the conference call, please dial (877) 407-8031 (domestic) or (201) 689-8031 (international). A replay of the call will be available from 11:00 a.m. EDT on August 11 until September 11, 2009 at midnight. To access the replay, please dial (877) 660-6853 (domestic) or (201) 612-7415 (international) and reference the account # 286 and the conference id # 329257. A live audio webcast of the call and the archived webcast will be available in the News and Events section of the Inhibitex website at http://www.inhibitex.com.

About Inhibitex

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to treat serious infectious diseases. The Company’s pipeline includes FV-100, its clinical-stage oral nucleoside analogue in development for the treatment of herpes zoster (shingles), as well as a series of HCV nucleoside polymerase inhibitors and HIV integrase inhibitors. Inhibitex has also licensed the use of its proprietary MSCRAMM® protein technology to Wyeth for the development of staphylococcal vaccines.

For additional information about the Company, please visit www.inhibitex.com.





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
about 17 minutes ago $JNJ Zytiga, a Prostate Cancer Drug, Does Well in Trial http://t.co/v7YUm9b6
about 1 hour ago $PFE Pfizer Lung Drug Stops Deadly Child Cancers in Study | http://t.co/hcfdrnCY
about 2 hours ago Human Genome Looks to Anyone but GlaxoSmithKline | http://t.co/d4IMkIn3
about 3 hours ago When David Einhorn did not mention Herbalife $HLF as a potential short candidate, that stock shot up on Wednesday | http://t.co/XpFKihQS
about 4 hours ago Stock Market: Stocks Get Hammered On Disappointing Data, Greece Worries http://t.co/FyH8zpru
about 4 hours ago Synergy Pharmaceuticals (SGYP) May Be Ready To Roll - Small Cap Stock Market Investing Tips http://t.co/FHYXlF1Q
about 7 hours ago Alvine Presents Results from Phase 2A Trial of ALV003 in Celiac Disease Patients -2012 Digestive Diseases Week Meeting http://t.co/e6Rjhbj9
about 7 hours ago Newly discovered protein makes sure brain development isn't 'botched' http://t.co/ZcUMTZSg

navigation

Free Phone Trade Alerts

Benzinga.com supporter Seeking Alpha Certified